Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00746681 | Investigation of Tolterodine, Pregabalin and a Tolterodine - Pregabalin Combination for the Treatment of Overactive Bladder | PHASE2 | COMPLETED | 188 | — | — | Dec 1, 2005 | Nov 1, 2006 | Dec 21, 2009 | 23 | Czechia, Lithuania +4 |
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | Tolterodine SR 2 mg once daily combined with pregabalin 75 mg twice daily |
| B | ACTIVE_COMPARATOR | Tolterodine SR 4 mg once daily |
| C | PLACEBO_COMPARATOR | Placebo |
| D | EXPERIMENTAL | Tolterodine SR 4 mg once daily combined with pregabalin 150 mg twice daily |
| E | EXPERIMENTAL | Pregabalin 150 mg twice daily |
| Name | Type | Description |
|---|---|---|
| Tolterodine & Pregabalin | DRUG | Tolterodine SR Oral, 2mg, once daily for 4 weeks Pregabalin, Oral, 75 mg, twice daily for 4 weeks |
| Tolterodine | DRUG | Tolterodine SR, Oral, 4 mg, once daily for 4 weeks |
| Placebo | DRUG | Placebo, Oral, twice daily for 4 weeks |
| Pregabalin | DRUG | Pregabalin, Oral, 150 mg twice daily for 4 weeks |
Inclusion Criteria: * Women \> 18 years Old * Diagnosis of OAB (micturition frequency \>/= 8 times per day; urinary urgency \>/= 4 times per week) Exclusion Criteria: * Subjects with symptoms of overactive bladder for less than 6 months prior to randomization. * Significant stress incontinence as...